SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Campisi T.) "

Sökning: WFRF:(Campisi T.)

  • Resultat 1-10 av 11
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • 2017
  • swepub:Mat__t
  •  
2.
  • Glasbey, JC, et al. (författare)
  • 2021
  • swepub:Mat__t
  •  
3.
  • 2021
  • swepub:Mat__t
  •  
4.
  •  
5.
  •  
6.
  • Fung, P. P. L., et al. (författare)
  • Time to onset of bisphosphonate-related osteonecrosis of the jaws : a multicentre retrospective cohort study
  • 2017
  • Ingår i: Oral Diseases. - : WILEY. - 1354-523X .- 1601-0825. ; 23:4, s. 477-483
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients.Subjects and Methods: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012.Results: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n=88) and 2.2years in those treated with zoledronate (n=218). Multivariable Cox regression showed that dentoalveolar surgery was inversely associated, and the use of antiangiogenics directly associated, with the TTO in patients with cancer treated with zoledronate.Conclusions: The incidence of ONJ increases with the duration of BP therapy, with notable differences observed with respect to BP type and potency, route of administration and underlying disease. When data are stratified by BP type, a time of 6.0 and 2.2years of oral alendronate and intravenous zoledronate therapy, respectively, is required for 50% of patients to develop ONJ. After stratification by disease, a time of 5.3 and 2.2years of BP therapy is required for 50% of patients with osteoporosis and cancer, respectively, to develop ONJ. These findings have significant implications for the design of future clinical studies and the development of risk-reduction strategies aimed at either assessing or modulating the risk of ONJ associated with BP.
  •  
7.
  •  
8.
  • Alajbeg, Ivan, et al. (författare)
  • Intraoralelectrostimulator for xerostomia relief : along-term, multicenter, open-label, uncontrolled, clinical trial
  • 2012
  • Ingår i: Oral surgery, oral medicine, oral pathology and oral radiology. - : Elsevier. - 2212-4403 .- 2212-4411. ; 113:6, s. 773-781
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: A previous sham-controlled multinational study demonstrated the short-term efficacy and safety for xerostomia treatment of an intraoral device that delivers electrostimulation to the lingual nerve. The objective of this study was to test the hypothesis that those beneficial effects would be sustained over an 11-month period. STUDY DESIGN: The device was tested on a mixed sample of 94 patients with xerostomia in an open-label, uncontrolled, prospective multicenter trial. Statutory outcome assessments were done at 5th, 8th, and 11th months and analyzed by multiple comparisons. RESULTS: Improvements achieved at month 5 from baseline were sustained throughout the follow-up period for the primary outcome, xerostomia severity, and the secondary outcomes resting whole salivary flow rate, xerostomia frequency, oral discomfort, and difficulties in speech, swallowing, and sleeping. No significant side effects were detected. CONCLUSIONS: The beneficial effects of a removable intraoral electrostimulating device were sustained for an 11-month period.
  •  
9.
  • Campisi, T., et al. (författare)
  • Perceived Pedestrian Level of Service : The case of Thessaloniki, Greece
  • 2022
  • Ingår i: Transportation Research Procedia. - : Elsevier BV. - 2352-1465. ; , s. 124-131
  • Konferensbidrag (refereegranskat)abstract
    • Level of Service (LOS) is one of the most crucial components for the assessment of pedestrian facilities by mainly concerning the effective width as well as pedestrians’ flows. However, current research reveals that qualitative characteristics can also contribute to LOS estimation as perceived by pedestrians. Specifically, socio-demographic characteristics (i.e., age, gender) as well as characteristics related with perceived comfort and safety can be related with perceived LOS. A Revealed Preference (RP) face to face questionnaire-based survey (including 301 interviewees) was realized during October 2019 at a central pedestrian facility in the city of Thessaloniki, Greece. RP questionnaire survey assisted in gaining valuable knowledge concerning the factors that mainly affect pedestrians’ perceived LOS across the pedestrian facility. The examined pedestrian facility is one of the most important in Thessaloniki since it facilitates high pedestrian flows within the city center daily. The present survey considered pedestrians’ general mobility characteristics such as walking frequency along the facility and trip purpose. Additionally, the evaluation of the greater facility’ area in terms of land use attractiveness, comfort, personal and road safety, public transport, parking conditions and traffic delays, accessibility, pedestrians and bicycles were concerned as well. Ordinal regression was the main tool for the development of the ordinal regression model, and therefore, for the conclusions’ drawing of the present research. The findings regarding perceived LOS can pave the way towards the design of sustainable policy concerning pedestrian facilities as well as the encouragement of active transport in urban areas.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 11

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy